BRPI0515581A - métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer - Google Patents

métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer

Info

Publication number
BRPI0515581A
BRPI0515581A BRPI0515581-9A BRPI0515581A BRPI0515581A BR PI0515581 A BRPI0515581 A BR PI0515581A BR PI0515581 A BRPI0515581 A BR PI0515581A BR PI0515581 A BRPI0515581 A BR PI0515581A
Authority
BR
Brazil
Prior art keywords
products
computer program
optimization
analysis
program methods
Prior art date
Application number
BRPI0515581-9A
Other languages
English (en)
Inventor
Raphael Marcelpoil
Clark Merrill Whitehead
Timothy J Fischer
Original Assignee
Tripath Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripath Imaging Inc filed Critical Tripath Imaging Inc
Publication of BRPI0515581A publication Critical patent/BRPI0515581A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

"MéTODOS E PRODUTOS DE PROGRAMA DE COMPUTADOR PARA ANáLISE E OTIMIZAçãO DE CANDIDATOS MARCADORES PARA PROGNóSTICO DE CáNCER". Métodos e produtos de programa de computador para avaliação de e otimização de um ou mais marcadores para uso no estabelecimento de um prognóstico para um paciente sofrendo de uma doença são proporcionados. Mais particularmente, os métodos incluem etapas para avaliação sistemática de uma série de características que podem ser extraídas de uma imagem de uma amostra corporal, tal como uma lâmina histológica, que tenha sido esposta a um ou mais biomarcadores, de modo a estabelecer uma regra de decisão prognóstica baseado em uma ou mais das características extraídas, de modo que a regra de decisão proporciona um prognóstico que é otimamente previsível da expectativa real para o paciente. Assim, os método e produtos de programa de computador proporcionados fornecem prognósticos otimamente previsíveis para auxiliar os médicos a desenvolver estratégias para tratamento eficaz do paciente.
BRPI0515581-9A 2004-09-22 2005-09-22 métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer BRPI0515581A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61207304P 2004-09-22 2004-09-22
US61196504P 2004-09-22 2004-09-22
PCT/US2005/033931 WO2006036726A1 (en) 2004-09-22 2005-09-22 Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis

Publications (1)

Publication Number Publication Date
BRPI0515581A true BRPI0515581A (pt) 2008-07-29

Family

ID=35695736

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0515581-9A BRPI0515581A (pt) 2004-09-22 2005-09-22 métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer
BRPI0515562-2A BRPI0515562A (pt) 2004-09-22 2005-09-22 métodos e composições para avaliação do prognóstico do cáncer de mama

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0515562-2A BRPI0515562A (pt) 2004-09-22 2005-09-22 métodos e composições para avaliação do prognóstico do cáncer de mama

Country Status (11)

Country Link
US (3) US20060063190A1 (pt)
EP (2) EP1805676A1 (pt)
JP (2) JP2008513032A (pt)
KR (2) KR20070061893A (pt)
AT (1) ATE520988T1 (pt)
AU (2) AU2005289756B2 (pt)
BR (2) BRPI0515581A (pt)
CA (2) CA2580795A1 (pt)
IL (2) IL182062A0 (pt)
MX (1) MX2007003502A (pt)
WO (2) WO2006036788A2 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8594410B2 (en) * 2006-08-28 2013-11-26 Definiens Ag Context driven image mining to generate image-based biomarkers
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
US8114615B2 (en) 2006-05-17 2012-02-14 Cernostics, Inc. Method for automated tissue analysis
KR100786759B1 (ko) * 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
CA2657576C (en) 2006-07-14 2023-10-31 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
JP2010500577A (ja) * 2006-08-07 2010-01-07 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 癌の予後および予測シグナチャーのプロテオミクスパターン
US8697373B2 (en) 2006-10-06 2014-04-15 Clarient Diagnostic Services, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
EP2156370B1 (en) 2007-05-14 2011-10-12 Historx, Inc. Compartment segregation by pixel characterization using image data clustering
EP2162728B1 (en) * 2007-06-15 2016-07-27 Novartis AG Microscope system and method for obtaining standardized sample data
US20100221722A1 (en) * 2007-06-15 2010-09-02 University Of North Carolina At Chapel Hill Methods for evaluating breast cancer prognosis
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) * 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009029810A1 (en) * 2007-08-31 2009-03-05 Historx, Inc. Automatic exposure time selection for imaging tissue
EP2034027A1 (en) * 2007-09-04 2009-03-11 Siemens Healthcare Diagnostics GmbH Molecular markers to predict response to chemotherapy and EGFR family inhibiton by targeted strategies
AU2008294687A1 (en) * 2007-09-07 2009-03-12 Universite Libre De Bruxelles Methods and tools for prognosis of cancer in ER- patients
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
WO2009055480A2 (en) * 2007-10-22 2009-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tgf-beta gene expression signature in cancer prognosis
WO2009089521A2 (en) * 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
WO2009158620A2 (en) * 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis methods of use thereof
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2010033508A1 (en) 2008-09-16 2010-03-25 Historx, Inc. Reproducible quantification of biomarker expression
US20100124747A1 (en) * 2008-11-03 2010-05-20 University Of Southern California Compositions and methods for diagnosis or prognosis of testicular cancer
US20100120080A1 (en) * 2008-11-03 2010-05-13 Quest Diagnostics Investments Incorporated Cancer diagnosis using ki-67
KR101141103B1 (ko) * 2009-12-15 2012-05-02 계명대학교 산학협력단 임상진단 결정 규칙 생성 방법
WO2011120984A1 (en) * 2010-03-31 2011-10-06 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
WO2011139721A1 (en) * 2010-04-27 2011-11-10 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US9129426B2 (en) * 2010-08-31 2015-09-08 General Electric Company Motion compensation in image processing
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images
ES2739623T3 (es) 2011-03-17 2020-02-03 Cernostics Inc Sistemas y composiciones para diagnosticar el esófago de Barrett y métodos para usarlos
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2761300A4 (en) * 2011-09-27 2015-12-02 Univ Michigan Recurrent genital fusion in breast cancer
US9115388B2 (en) 2011-11-01 2015-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene signature for the prediction of NF-kappaB activity
WO2013067268A1 (en) * 2011-11-03 2013-05-10 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
US8885912B2 (en) * 2011-11-03 2014-11-11 General Electric Company Generate percentage of positive cells for biomarkers by normalizing and autothresholding the image intensity produced by immunohistochemistry technique
WO2013159099A2 (en) * 2012-04-20 2013-10-24 Memorial Sloan-Kettering Cancer Center Gene expression profiles associated with metastatic breast cancer
WO2013164280A1 (en) * 2012-04-30 2013-11-07 General Electric Company Systems and methods for analyzing biomarker co-localization in a biological tissue
US8737709B2 (en) * 2012-04-30 2014-05-27 General Electric Company Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
CN104823053A (zh) * 2012-07-27 2015-08-05 利昂贝拉尔中心 ERα/Src/PI3K复合物的检测作为乳腺癌的预测标志
JP2014123230A (ja) * 2012-12-20 2014-07-03 Sony Corp 画像処理装置、画像処理方法、及び、プログラム
CN103136333B (zh) * 2013-01-29 2016-08-10 冯力新 一种抽象属性的量化评价分析方法
CN103293321B (zh) * 2013-05-27 2015-05-13 北京大学 一种检测dna损伤诱导的早期核仁应激的试剂盒及其应用
EP3033079B1 (en) 2013-08-12 2018-10-31 Pharmacyclics LLC Methods for the treatment of her2 amplified cancer
US9519823B2 (en) * 2013-10-04 2016-12-13 The University Of Manchester Biomarker method
US9953417B2 (en) 2013-10-04 2018-04-24 The University Of Manchester Biomarker method
US9785752B1 (en) * 2014-02-25 2017-10-10 Flagship Biosciences, Inc. Method for stratifying and selecting candidates for receiving a specific therapeutic approach
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US20170176440A1 (en) * 2014-03-27 2017-06-22 The Board Of Regents Of The University Of Texas System Methods and compositions for evaluating breast cancer patients
EP3155592B1 (en) * 2014-06-10 2019-09-11 Leland Stanford Junior University Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides
HK1246653A1 (zh) 2014-11-17 2018-09-14 Context Biopharma Inc. 奥那司酮延长释放组合物和方法
US11543411B2 (en) 2014-12-05 2023-01-03 Prelude Corporation DCIS recurrence and invasive breast cancer
US20180040120A1 (en) * 2014-12-29 2018-02-08 Flagship Biosciences, Inc. Methods for quantitative assessment of mononuclear cells in muscle tissue sections
KR101765999B1 (ko) 2015-01-21 2017-08-08 서울대학교산학협력단 암 바이오마커의 성능 평가 장치 및 방법
WO2016123525A1 (en) * 2015-01-30 2016-08-04 Raytheon Company Apparatus and methods for classifying and counting corn kernels
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
ES2831754T3 (es) 2015-11-25 2021-06-09 Cernostics Inc Métodos para predecir la progresión del esófago de Barrett
CA3007292A1 (en) * 2015-12-02 2017-06-08 Clearlight Diagnostics Llc Methods for preparing and analyzing tumor tissue samples for detection and monitoring of cancers
EP3389632A4 (en) 2015-12-15 2019-11-06 Context Biopharma Inc. AMORPHIC ONAPRISTON COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2017139367A1 (en) 2016-02-08 2017-08-17 Imago Systems, Inc. System and method for the visualization and characterization of objects in images
WO2017156627A1 (en) * 2016-03-14 2017-09-21 Proteocyte Diagnostics Inc. Automated method for assessing cancer risk using tissue samples, and system therefor
DK3430022T3 (da) 2016-03-14 2020-05-18 Somalogic Inc Forbindelser og fremgangsmåder til syntese af 5-(N-beskyttet-tryptaminocarboxyamid)-2'-deoxyuridin-phosphoramidit til inkorporering i en nukleinsyresekvens
WO2017182985A1 (en) * 2016-04-20 2017-10-26 Morphotek, Inc. Prognosis of serous ovarian cancer using biomarkers
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
CA3108862A1 (en) 2017-08-07 2019-02-14 Imago Systems, Inc. System and method for the visualization and characterization of objects in images
WO2020056338A1 (en) 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
US12260607B2 (en) 2018-12-15 2025-03-25 The Brigham And Women's Hospital, Inc. Augmented digital microscopy for lesion analysis
EP4182480B1 (en) 2020-07-17 2025-05-07 European Molecular Biology Laboratory Prognostic biomarkers for cancer
CN114959026A (zh) * 2022-04-15 2022-08-30 深圳市陆为生物技术有限公司 检测基因的试剂在制备用于评价乳腺癌患者复发风险的产品中的应用
TW202440117A (zh) 2023-01-06 2024-10-16 美商愛德亞生物科學公司 使用parg調節劑治療癌症之方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1994000591A1 (fr) * 1992-06-26 1994-01-06 Nippon Shinyaku Co., Ltd. Anticorps monoclonal, son procede d'obtention, cellule productrice de cet anticorps, et methode de diagnostic
JPH09509487A (ja) * 1994-02-14 1997-09-22 ニューロメディカル システムズ インコーポレイテッド 細胞試料自動分類装置及び方法
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5869040A (en) * 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
JP2002514098A (ja) * 1996-08-25 2002-05-14 センサー インコーポレイテッド 虹彩取得用イメージのための装置
US5798266A (en) * 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
AU5066098A (en) * 1996-11-22 1998-06-10 Shiloov Medical Technologies Ltd. A whole blood/mitogen assay for the early detection of a subject with cancer and kit
WO2000024940A1 (en) * 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers
WO2000047998A1 (en) * 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
EP1159619A2 (en) * 1999-03-15 2001-12-05 EOS Biotechnology, Inc. Methods of diagnosing and treating breast cancer
US6642009B2 (en) * 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
US20030087265A1 (en) * 2000-01-21 2003-05-08 Edward Sauter Specific microarrays for breast cancer screening
CA2399934A1 (en) * 2000-04-04 2001-10-11 Medical Research Council Methods involving induced dimerisation by cellular components
WO2001080890A2 (en) * 2000-04-26 2001-11-01 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
GB0011439D0 (en) * 2000-05-12 2000-06-28 Novartis Res Found Cancer diagnosis and assays for screening
US7118853B2 (en) * 2000-07-26 2006-10-10 Applied Genomics, Inc. Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
US6703204B1 (en) * 2000-07-28 2004-03-09 The Brigham & Women's Hospital, Inc. Prognostic classification of breast cancer through determination of nucleic acid sequence expression
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
DE60239535D1 (de) * 2001-06-18 2011-05-05 Rosetta Inpharmatics Llc Diagnose und prognose von brustkrebspatientinnen
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
JP3721105B2 (ja) * 2001-08-22 2005-11-30 日本電気株式会社 組織検査法を利用する胃癌の切除手術後の予後検査方法
US7065236B2 (en) * 2001-09-19 2006-06-20 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
US6855554B2 (en) * 2001-09-21 2005-02-15 Board Of Regents, The University Of Texas Systems Methods and compositions for detection of breast cancer
US20040002067A1 (en) * 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US7133547B2 (en) * 2002-01-24 2006-11-07 Tripath Imaging, Inc. Method for quantitative video-microscopy and associated system and computer software program product
WO2003069307A2 (en) * 2002-02-14 2003-08-21 The Johns Hopkins University School Of Medicine Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040229299A1 (en) * 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1613732A4 (en) * 2003-04-01 2012-03-14 Monogram Biosciences Inc INTRA-CELLULAR COMPLEXES AS BIOMARKERS
KR20150132601A (ko) * 2003-11-17 2015-11-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
US20050221398A1 (en) * 2004-01-16 2005-10-06 Ipsogen, Sas, A Corporation Of France Protein expression profiling and breast cancer prognosis
EP1704416A2 (en) * 2004-01-16 2006-09-27 Ipsogen Protein expression profiling and breast cancer prognosis
KR20080075045A (ko) * 2004-03-24 2008-08-13 트리패스 이미징, 인코포레이티드 자궁경부 질환의 검사 방법 및 조성물

Also Published As

Publication number Publication date
EP1800130A2 (en) 2007-06-27
JP2008513032A (ja) 2008-05-01
AU2005289756B2 (en) 2011-10-13
MX2007003502A (es) 2007-10-10
BRPI0515562A (pt) 2008-07-29
EP1800130B1 (en) 2011-08-17
CA2580937A1 (en) 2006-04-06
CA2580795A1 (en) 2006-04-06
KR20070061893A (ko) 2007-06-14
ATE520988T1 (de) 2011-09-15
EP1805676A1 (en) 2007-07-11
AU2005289728A1 (en) 2006-04-06
US20060078926A1 (en) 2006-04-13
WO2006036788A3 (en) 2006-08-17
CA2580937C (en) 2016-02-02
KR20070068401A (ko) 2007-06-29
US20060063190A1 (en) 2006-03-23
IL182063A0 (en) 2008-04-13
IL182062A0 (en) 2007-07-24
WO2006036788A2 (en) 2006-04-06
US20090269856A1 (en) 2009-10-29
WO2006036726A1 (en) 2006-04-06
AU2005289728B2 (en) 2011-11-24
JP5184087B2 (ja) 2013-04-17
AU2005289756A1 (en) 2006-04-06
JP2008513793A (ja) 2008-05-01
US7899623B2 (en) 2011-03-01

Similar Documents

Publication Publication Date Title
IL182062A0 (en) Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
Moul et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases
Mobasheri et al. Biomarkers of (osteo) arthritis
Kawaguchi et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases
Pineda-Tenor et al. Biological variation and reference change values of common clinical chemistry and haematologic laboratory analytes in the elderly population
Mahar et al. Critical assessment of clinical prognostic tools in melanoma
Hank et al. A combination of biochemical and pathological parameters improves prediction of postresection survival after preoperative chemotherapy in pancreatic cancer: the PANAMA-score
Deng et al. Size-adjusted quantitative Gleason score as a predictor of biochemical recurrence after radical prostatectomy
Taguchi et al. Symptoms at diagnosis as independent prognostic factors in retroperitoneal liposarcoma
Ramsey et al. Simulation modeling of outcomes and cost effectiveness
Chen et al. MethylPCA: a toolkit to control for confounders in methylome-wide association studies
Cerhan et al. Risk factors for progression to new sites of radiographically defined osteoarthritis in women.
Modi et al. Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A SEER Analysis
Lamberton et al. Comparing and distinguishing the structure of biological branching
Meyskens Jr et al. Principles of cancer prevention
Venkatesh et al. Differentially expressed genes in tumors of prostate cancer in American patients with European and African origin
Arsene et al. Artificial neural networks used in the survival analysis of breast cancer patients: a node-negative study
Schold The promise and reality of machine-learning models in kidney transplantation
Vuik et al. Understanding population health needs: How data-driven population segmentation can support the planning of integrated care
Cook-Deegan et al. Gene patents and licensing: Case studies prepared for the Secretary's Advisory Committee on Genetics, Health, and Society
Liu et al. A Predictive Model Based on Machine Learning for Early Progression/Relapse of Follicular Lymphoma
Jabbar et al. Incidental thyroid carcinoma
Jeong et al. Deep learning-driven whole-slide image analysis predicts chemo-resistance and motility subtypes in muscle-invasive bladder cancer
Skirgård Ha nie
Roque et al. Interim FDG-PET/CT Is an Independent Predictor of Overall Survival and Progression Free Survival in a Real-Life Cohort

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.